Thyroid Cancer

Latest News

Results from the phase 2b TACTI-003 trial show that eftilagimod alfa plus pembrolizumab achieved high objective response and disease control rates.
Eftilagimod Alfa Combo Appears Efficacious in Head and Neck Cancer

July 12th 2024

Results from the phase 2b TACTI-003 trial show that eftilagimod alfa plus pembrolizumab achieved high objective response and disease control rates.

As the practice of radiation therapy evolves in HPV-associated OPSCC, updated evidence-based ASTRO guidelines may help inform clinical practices.
ASTRO Updates Guidelines for Radiation Therapy in HPV-Associated OPSCC

June 21st 2024

Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Selpercatinib Earns Full FDA Approval Status in RET+ Thyroid Cancer

June 12th 2024

Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
Selpercatinib Earns Accelerated Approval in Pediatric RET+ Thyroid Cancer

May 29th 2024

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.
FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC

May 15th 2024

More News